Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2021

01-08-2021 | Correction

Correction to: An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy

Authors: Sahand Imani, Hergen Buscher, Richard Day, Sheridan Gentili, Graham R. D. Jones, Debbie Marriott, Ross Norris, Indy Sandaradura

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2021

Login to get access

Excerpt

Correction to: European Journal of Clinical Microbiology & Infectious Diseases (2018) 37:2171–2175
Metadata
Title
Correction to: An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy
Authors
Sahand Imani
Hergen Buscher
Richard Day
Sheridan Gentili
Graham R. D. Jones
Debbie Marriott
Ross Norris
Indy Sandaradura
Publication date
01-08-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2021
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-021-04291-6

Other articles of this Issue 8/2021

European Journal of Clinical Microbiology & Infectious Diseases 8/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine